Targeting a

Fuller Life

Rain Therapeutics researches, develops and translates innovative targeted cancer therapies for patients

Rain Therapeutics is focused on patients struggling with difficult cancers, and we help provide them hope to get their lives back.

Scientific programs

Rain’s programs  target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.

MilademetaN

Rain’s lead drug candidate, milademetan, is an oral small molecule, inhibitor of mouse double minute 2 (MDM2). It is in clinical development  in patients with liposarcoma and other MDM2 - dependent cancers.

Rad52 Research program

Rain’s RAD52 research program is currently in preclinical development. RAD52 plays a central role in the DNA Damage Response (DDR) pathway.

Resources & Publications

Rain in the News

Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination with Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
January 5, 2022 8:00 AM
Rain Therapeutics Inc., (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a clinical supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab.
Rain Therapeutics to Present at Upcoming Investor Conferences
December 21, 2021 8:00 AM
Rain Therapeutics Inc., (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the JP Morgan Chase 40th Annual Healthcare Conference and at the H.C. Wainwright Bioconnect Conference, both conferences being held virtually January 10-13, 2022.
Rain Therapeutics, Inc. Added to the NASDAQ Biotechnology Index
December 14, 2021 8:00 AM
(GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.